SecBot SecBot
6-K ·Filed Jun 11, 2026

GMAB

GENMAB A/S
NEUTRAL
Impact 2/10
Horizonmonths Processed5mo ago SEC0001434265-26-000087
Notable filing: 6-K
Actionable Insight • Neutral

No trade signal. This is a standard employee compensation grant with no immediate financial or strategic implications. Monitor next quarterly filing for any changes in outstanding share count from ongoing equity programs.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$25.24
T+0 close · Jun 11, 2026 · via day close
Latest settled
+33.12%
T+60 · $33.60
Vs SPY
+28.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 11 $25.24entry
  2. T+1 · 5mo ago −0.63%α −1.17% · $25.08
  3. T+5 · 5mo ago +0.59%α +0.16% · $25.39
  4. T+20 · 4mo ago +17.99%α +16.10% · $29.78
  5. T+60 · 2mo ago +33.12%α +28.73% · $33.60
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Genmab A/S filed a 6-K reporting a routine grant of 15,894 restricted stock units and 15,494 warrants to employees. The grants are standard long-term incentive compensation with 3-year vesting, representing a minimal and immaterial dilution relative to the company's $15.7B market cap.

Key Facts

  • Grant of 15,894 restricted stock units and 15,494 warrants to employees on June 11, 2026.
  • RSU fair value of DKK 1,616.50 per unit (closing price on grant date); warrant fair value of DKK 534.23 per warrant (Black-Scholes).
  • Both instruments vest three years from grant date; warrants expire at the seventh anniversary.
  • The awards are cost-free to recipients; exercise price per warrant is DKK 1,616.50.
  • Total potential dilution is negligible relative to Genmab's outstanding share count (~$15.7B market cap).

Financial Impact

Immaterial, combined fair value of roughly DKK 33.9M (~$4.8M) based on RSU fair value of ~DKK 25.7M and warrant fair value of ~DKK 8.3M; this is less than 0.03% of market cap.

dilutionshare count

Risk Factors

  • None from this filing; equity compensation programs are routine for a biotech company.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001434265-26-000087
Document: gmab_20260611xx6k.htm0001434265-26-000087
Document: 0001434265-26-000087-index-headers.html0001434265-26-000087
Document: 0001434265-26-000087-index.html0001434265-26-000087
Document: 0001434265-26-000087.txt0001434265-26-000087

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 11, 2026